Prime Medicine Inc. (PRME)
NASDAQ: PRME
· Real-Time Price · USD
1.19
0.01 (0.85%)
At close: Jun 02, 2025, 3:59 PM
1.19
0.20%
After-hours: Jun 02, 2025, 07:34 PM EDT
Company Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology.
It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine Inc.
| Country | United States |
| IPO Date | Oct 20, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 214 |
| CEO | Dr. Jeremy S. Duffield M.D., Ph.D. |
Contact Details
Address: 21 Erie Street Cambridge, Massachusetts United States | |
| Website | https://www.primemedicine.com |
Stock Details
| Ticker Symbol | PRME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001517936 |
| CUSIP Number | 74168J101 |
| ISIN Number | US74168J1016 |
| Employer ID | 00-0000000 |
| SIC Code |
Key Executives
| Name | Position |
|---|---|
| Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 23, 2025 | 485BXT | Filing |
| May 22, 2025 | 4 | Filing |
| May 22, 2025 | 4 | Filing |
| May 22, 2025 | 4 | Filing |
| May 19, 2025 | 4 | Filing |
| May 19, 2025 | 4 | Filing |
| May 19, 2025 | DEFA14A | Filing |
| May 19, 2025 | 8-K | Current Report |
| May 15, 2025 | 40-APP/A | [Amend] Filing |
| May 13, 2025 | DEFA14A | Filing |